cemsidomide
CFT7455 Small Molecule Target: IKZF1, IKZF3, IKZF1/3, cereblon
C4 Therapeutics
Most recent annual filing: 2026-02-15
- cemsidomide corporate updateMid-2026cemsidomide corporate update, Mid-2026, notable
- internal discovery pipeline IND candidateEnd of 2026internal discovery pipeline IND candidate, End of 2026, routine
- partnered pipeline partnershipBy year-end 2026partnered pipeline partnership, By year-end 2026, routine
- cemsidomide + elranatamab Ph1 start1H 2027cemsidomide + elranatamab Ph1 start, 1H 2027, notable
- cemsidomide MOMENTUM trial enrollment done1Q 2027cemsidomide MOMENTUM trial enrollment done, 1Q 2027, routine
- cemsidomide + elranatamab Ph1 readoutMid-2027cemsidomide + elranatamab Ph1 readout, Mid-2027, major
- cemsidomide MOMENTUM trial Ph2 interim2H 2027cemsidomide MOMENTUM trial Ph2 interim, 2H 2027, notable
- MOMENTUM enrollment done2H 2027MOMENTUM enrollment done, 2H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
CFT8919
- Undisclosed indication
Technology platforms
TORPEDO
Proprietary targeted protein degradation platform — collection of computational and experimental tools for designing, analyzing, and predicting degrader performance; supports MonoDAC (molecular glue type) and BiDAC (heterobivalent) degraders with properties such as oral bioavailability, CNS penetration, enhanced potency, and selectivity; focus on oncology, inflammation, neuroinflammation, and neurodegeneration
BIDAC · Roche
Bivalent degrader antibody conjugate platform technology used in collaboration with Roche for discovering and developing DACs against oncology targets.
Discontinued (1)
- CFT8919 — Non-Small Cell Lung Cancer · strategic deprioritization due to evolving treatment landscape, capital priorities, and available clinical data
Biotech Distilled coverage (5)
- 2026-08-12 UPDATE: C4 Therapeutics (CCCC) - They Sold Stock They Said They Didn’t Need 🔒 Paid
- 2026-06-12 UPDATE: C4 Therapeutics (CCCC) - The EHA Print Holds, and the Depth Story Gets Real
- 2026-05-12 UPDATE: C4 Therapeutics (CCCC) - The CFT8919 Bonfire and the All-In Bet on Cemsidomide 🔒 Paid
- 2026-04-11 UPDATE: C4 Therapeutics (CCCC) - Roche Validates the DAC Modality and Pads the Balance Sheet 🔒 Paid
- 2026-04-01 C4 Therapeutics (CCCC) - Scientific Deep Dive for Cemsidomide and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.